Literature DB >> 15008240

Colonic polyps of acromegalic patients are not associated with mutations of the peroxisome proliferator activated receptor gamma gene.

F Bogazzi1, F Ultimieri, F Raggi, D Russo, S Brogioni, C Cosci, M Gasperi, A Costa, P Viacava, F Mosca, L Bartalena, E Martino.   

Abstract

Peroxisome proliferator activated receptor (PPAR)gamma plays a pivotal role in regulating adipocyte differentiation and metabolism, but also has an antiproliferative effect in several tissues, including colonic mucosa, where it is highly expressed. Loss-of-function mutations have been reported in about 10% of sporadic primary colon cancer. Acromegalic patients have an increased prevalence of colonic neoplasms and lower PPARgamma levels in the colonic mucosa. Thus, PPARgamma may act as a tumor suppressor gene, and its reduced expression or loss-of-function mutations may contribute to tumorigenesis. In this study the expression and mutations of the PPARgamma gene in the colonic polyps and mucosa outside polyps were investigated in 10 acromegalic and 17 non-acromegalic patients. PPARgamma expression was evaluated by RT-PCR. PPARgamma was expressed in each sample, but expression appeared to be lower in polyps than in mucosa outside polyps from either acromegalic or non-acromegalic patients. All exons of the PPARgamma gene were directly sequenced after PCR amplification: no mutations were found either in acromegalic or in non-acromegalic patients. In conclusion, the results of this preliminary study suggest that the lower expression of PPARgamma rather than somatic mutations of this gene is involved in colonic tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15008240     DOI: 10.1007/bf03345249

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  26 in total

Review 1.  Peroxisome proliferator-activated receptors: nuclear control of metabolism.

Authors:  B Desvergne; W Wahli
Journal:  Endocr Rev       Date:  1999-10       Impact factor: 19.871

Review 2.  PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function.

Authors:  B B Lowell
Journal:  Cell       Date:  1999-10-29       Impact factor: 41.582

3.  Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

4.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Differentiation and reversal of malignant changes in colon cancer through PPARgamma.

Authors:  P Sarraf; E Mueller; D Jones; F J King; D J DeAngelo; J B Partridge; S A Holden; L B Chen; S Singer; C Fletcher; B M Spiegelman
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

6.  Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice.

Authors:  A M Lefebvre; I Chen; P Desreumaux; J Najib; J C Fruchart; K Geboes; M Briggs; R Heyman; J Auwerx
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

7.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Authors:  E Mueller; M Smith; P Sarraf; T Kroll; A Aiyer; D S Kaufman; W Oh; G Demetri; W D Figg; X P Zhou; C Eng; B M Spiegelman; P W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

8.  Opposite association of two PPARG variants with cancer: overrepresentation of H449H in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases.

Authors:  W M Smith; X P Zhou; K Kurose; X Gao; F Latif; T Kroll; K Sugano; S A Cannistra; S K Clinton; E R Maher; T W Prior; C Eng
Journal:  Hum Genet       Date:  2001-08       Impact factor: 4.132

9.  Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.

Authors:  T Tanaka; H Kohno; S Yoshitani; S Takashima; A Okumura; A Murakami; M Hosokawa
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

10.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Authors:  T Kubota; K Koshizuka; E A Williamson; H Asou; J W Said; S Holden; I Miyoshi; H P Koeffler
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

View more
  1 in total

1.  Adrenal morpho-functional alterations in patients with acromegaly.

Authors:  C Scaroni; R Selice; S Benedini; E De Menis; M Arosio; C Ronchi; M Gasperi; L Manetti; G Arnaldi; B Polenta; M Boscaro; N Albiger; E Martino; F Mantero
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.